hypertrophic cardiomyopathy - Cleveland Clinic

heart showing obstructive cardiomyopathy

March 29, 2024/Heart, Vascular and Thoracic/Clinical Cardiology

Mavacamten in the Real World: Study Demonstrates Safe Reduction in Eligibility for Septal Reduction Therapy

Logistic feasibility supported for treating obstructive HCM under the REMS program

23-CCC-3852617 ULTC_Endo ablation transmitral 650×450

May 17, 2023/Cleveland Clinic London

Case Report: First UK Experience with Ultra-Low Temperature Cryoablation for Ventricular Tachycardia Shows Promising Results

New technology aids a Cleveland Clinic London patient with a complex arrhythmia

22-HVI-2769712_hyptertrophic-cardiomyopathy_650x450

April 5, 2022/Heart, Vascular and Thoracic/Clinical Cardiology

Mavacamten Significantly Reduces Patients’ Need for Septal Reduction Therapy Over 16 Weeks

Longer-term confirmation of VALOR-HCM could yield a noninvasive therapy for severe obstructive HCM

November 14, 2019/Pediatrics/Patient Care & Management

Asymptomatic Aortic Dissection After Orthotopic Heart Transplantation in a Pediatric Patient

A case study

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

November 10, 2015/Heart, Vascular and Thoracic/News & Insights

Case Study in Cardiac Amyloidosis: Daunting But Ever More Treatable

Dual heart and stem cell transplants reflect progress

June 11, 2015/Heart, Vascular and Thoracic

To Prevent Sudden Death in Student Athletes, Look Beyond the ECG